

NUTRACEUTIC SUPPLEMENTATION IN THE TREATMENT OF BEDSORE LESIONS IN NEOPLASTIC PATIENTS AT HOME: SHORT TERM STUDY

Ruggeri E., Agostini F., Camedda L., Benfenati H., Giannantonio M., Pannuti F.

Fondazione ANT-Italy Onlus, Bologna.

Aym of the study

To check the short term efficacy of a nutraceutic supplementation with a specific product (*W-care*, Nutritional care Technology) in the treatment of bedsore lesions (BSL) in neoplastic patients in advanced stages , assisted at home by the Foundation ANT-Italy of Bologna

Materials and Methods

Characteristics of the Population

- Male: 4
- Female: 3
- Age: 81 + / 7.3 years
- Place of neoplasia: 2 myeloma, 2 lung, 1 prostate, 1 colon, 1 stomach.

Characteristics of bedsore lesions

- **Total:** 9 lesions (2 patients with double BSL).
- Etiopathogenesis: prolonged compression
- Place: 4 at sacrum, 3 at heel, 1 at trocanter and 1 on the leg.
- Stage on entry: 4 at stage II, 3 at stage III and 2 at stage IV.

Method

- Evaluation of clinical and nutritional parameters, using the entrance sheet:
- ✓ Seat of the tumour
- √ Therapy in progress
- ✓ Main symptoms
- ✓ Karnofsky Index (IK)
- ✓ Nutritional state evaluated against Body Mass Index (BMI: v.n. > 18.5)
- ✓ Total calorie intake noted with nutritional inquiry
- ✓ Total lymphocitemia (v.n. > 1800 mm³)
- ✓ albuminemia (v.n. > 3.5 g/dl)
- Evaluation of nursing parameters, using the entrance the sheet compiled at time T_0 - T_7 - T_{14} - T_{21} - T_{28} :
- ✓ Position of the bedsore lesions
- ✓ Number of lesions
- ✓ Etiopathogenesis of the lesions
- ✓ Risk evaluation (using Norton index)
- ✓ Stage of lesion (according to the N.P.U.A.P. classification)
- ✓ times and treatment methods of lesions preceding T₀
- ✓ Description and photos of lesions when established
- ✓ Patient compliance to the treatment
- Use of a product (W-care, sachets) with a base of specific nutrients:
- ✓ L-arginine
- √omega-3
- ✓ vitamin A-E-C-K and from B group
- ✓ zinc ✓ collage
- ✓ collagen
- Supplementation dosage:

II-III stage: 2 sachets/per day; IV stage: 3 sachets/per day.

Follow up: 4 weeks

Result

At start of the study (T_0) :

√The bedsore lesions were in treatment for an average 63 +/- 72 days (range: 20-240 days) with medication which was administered on average on 4 days of the week.


✓The intravenous calorie intake and nutritional state were in the normal range for 5 out of 7 patients (for an overall 7 BSL at Stage II and III).


✓In 2 patients with Stage IV lesions, a slight-moderate level of malnutrition was present (BMI=17.5 and 18; total lymphocytes=1120 and 890; albuminemia=2.6 and 2.8) .The total calorie intake was in both < 50% of total energy needs.

After 4 weeks of treatment (T_{28}) :

√The 7 bedsore lesions at Stages II and III were completely healed.


√The 2 lesions at Stage IV had improved, with a reduction of the stage and the dimensions (see photo).





✓ Compliance with the product showed a good result in all patients

Nutraceutic supplementation: development of lesions (7 patients, 9 BSL)



Conclusions

The healing at T_{28} of Stage II and III lesions shows the efficacy of W-care in the treatment of bedssore lesions in the short term.

The fact that there was only an improvement in the two mal-nourished patients with Stage IV lesions confirms **the importance of an adequate nutritional state** and suggests the need to increase the nutraceutic supplementation in this category of patient.